Endometrial Serous Adenocarcinoma Clinical Trial
Official title:
A Phase 0 Window-of-Opportunity Pharmacodynamic Trial of Triapine (NSC# 663249) in Uterine Corpus Serous Adenocarcinoma
This early phase I trial investigates the response to the anti-cancer drug, triapine, in uterine cancers by using markers from tissue samples at the time of removal of the uterus, ovaries, and fallopian tubes (hysterectomy and bilateral salpingo-oophorectomy). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Adding triapine to the usual approach of surgery followed by chemotherapy alone or in combination with radiation therapy may help to slow the growth of uterine cancer.
PRIMARY OBJECTIVE: I. Determine whether intravenous (IV) triapine 25 mg/m^2 will induce cell cycle arrest as measured by phospho-histone H3 (pHH3) in uterine serous adenocarcinoma cells removed at the time of hysterectomy. SECONDARY OBJECTIVES: I. Determine whether a preoperative dose of intravenous triapine 25 mg/m^2 can be safely given prior to hysterectomy and staging for uterine serous adenocarcinoma. II. Determine whether changes in cyclin D/E and Ki-67 protein expression are detectable using immunohistochemistry pre- and post-triapine treatment in uterine serous adenocarcinomas. III. Evaluate plasma and tissue triapine concentrations. EXPLORATORY OBJECTIVES: I. Determine the feasibility of using single-cell transcriptome analysis to quantify changes in gene expression following triapine treatment and to evaluate their concordance with immunohistochemistry (IHC) endpoints of cell cycle arrest. II. Identify genomic variants of uterine serous adenocarcinoma (including but not limited to p53) with treatment response to ribonucleotide reductase inhibitors such as triapine using whole exome sequencing (WES). OUTLINE: Patients receive triapine IV over 2 hours on day 1. Patients then undergo surgical resection and tissue collection 6-8 hours after the initiation of the triapine infusion. Patients also undergo biopsy and collection of blood samples on study. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01010126 -
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
|
Phase 2 | |
Completed |
NCT01935973 -
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03660826 -
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
|
Phase 2 | |
Completed |
NCT01642082 -
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT01440998 -
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
|
Phase 1 | |
Completed |
NCT02728258 -
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00977574 -
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT01225887 -
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT01005329 -
Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT05256225 -
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03836157 -
Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
|
Phase 2 | |
Suspended |
NCT04585958 -
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02142803 -
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT00807768 -
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
|
Phase 3 | |
Completed |
NCT02501954 -
Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol
|
Phase 3 | |
Completed |
NCT01307631 -
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02065687 -
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT02874430 -
Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer
|
Phase 2 | |
Completed |
NCT01210222 -
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00942357 -
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
|
Phase 3 |